$tacks Upon $tacks Of Moolah (STAX)

[ProfitScout]

$TKMO: Annual Letter to Shareholders, 2024 In Review
News Link:
https://www.globenewswire.com/news-release/2025/01/07/3005425/0/en/Annual-Letter-to-Shareholders-2024-In-Review.html

[ProfitScout]

$BLIS News covering pending $370 Million contract: NAPC Defense (OTCPK: BLIS) issues new Progress Report regarding Large Contract with Saudi Arabia, Live-Fire Demos for U.S. based Police and SWAT, Manufacturing update, and more

LARGO, Fla., Dec. 12, 2024 (GLOBE NEWSWIRE) -- NAPC Defense, Inc., (OTCPK: BLIS) (“NAPC” or “the Company”) announces that the Company is making strong progress on its CornerShot USA weapons systems and other initiatives.

NAPC’s Management believes the Company is well positioned to drive significant revenue and profits in 2025, from its own manufacturing and sale of CornerShot in the United States and Saudi Arabia. NAPC maintains it will also drive revenue through the brokering of arms and munitions, as well as contract work for renovation and clean up, following recent hurricanes in the area.

As previously announced, NAPC received a signed and stamped Letter of Intent from Saudi Arabia for an initial order of 37,000 CornerShot units, valued at (U.S.) $370 million. Management has already conducted critical late-stage meetings and live-fire demonstrations in Saudi Arabia with several military divisions through visits to the country in August and October of 2024.

NAPC Defense has now received a request to complete live fire demonstrations in Saudi Arabia from Saudi Land Forces. The visit is planned to take place between December 29, 2024 and January 12, 2025. The Company previously reported that this upcoming visit would take place last month.

Please see below for a list of current and anticipated NAPC developments, as we enter the New Year:

Following the next phase of the upcoming CornerShot demonstrations in Saudi Arabia, NAPC expects that it will enter final contract negotiations, deposit funding, and initial CornerShot manufacturing. in Q1 of 2025.
NAPC has secured manufacturing facilities for the production of CornerShot USA weapons systems in Pinellas Park, FL. The space is large enough to meet anticipated demand for the near future.
Live-fire demonstrations were recently conducted for St. Petersburg Police and SWAT teams in Pinellas County. New orders from these departments, as well as others, are expected in January 2025.
NAPC Defense has secured booth space #10953 at the upcoming SHOT Show in Las Vegas from January 21-24, 2025. The SHOT Show is the largest and most comprehensive trade show for all professionals involved with the shooting sports, hunting and law enforcement industries.
In addition to over $1.5 million in new hurricane renovation and cleanup work in Pinellas Country, the Company has partnered with another firm in an effort to win an additional $3 million in contracts.
CEO Kenny West stated, “This is truly an exciting time for NAPC Defense. We have laid the groundwork in 2024, and now it’s time to deliver in 2025. We appreciate the ongoing support from our shareholders and investors.”

About NAPC Defense, Inc.

NAPC Defense, Inc. https://www.napcdefense.com/ is an armament sales and production company, fully licensed in the United States, with exclusive rights to produce and sell CornerShot USA weapons systems in the U.S and Saudi Arabia, in addition to brokering arms and munitions throughout the world all with US State Department approval. Additional smaller weapons platforms, a series of ballistics protection technologies and related products are in development or being finalized for sale.

FORWARD LOOKING STATEMENTS:

This press release and the statements of representatives of NAPC (the "Company") related thereto contain, or may contain, among other things, "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact included herein are "forward-looking statements," including any other statements of non-historical information.

These forward-looking statements are subject to significant known and unknown risks and uncertainties and are often identified by the use of forward-looking terminology such as "guidance," "projects," "may," "could," "would," "should,’ “believes," "expects," "anticipates,” “estimates," "intends," "plans, “ultimately" or similar expressions. All forward-looking statements involve material assumptions, risks and uncertainties, and the expectations contained in such statements may prove to be incorrect. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company's actual results (including, without limitation, NAPC's ability to advance its business, generate revenue and profit and operate as a public company) could differ materially from those stated or anticipated in these forward-looking statements as a result of a variety of factors, including factors and risks discussed in the periodic reports that the Company files with the SEC. All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. The Company undertakes no duty to update these forward-looking statements except as required by law.

COMPANY CONTACT:

Kenny West, CEO [phone] Ext.713

https://www.globenewswire.com/newsroom/ti?nf=OTMxODA3MiM2NjM0MDk5IzIyNjE1MDY=
https://ml.globenewswire.com/media/ZTE0MTNkZDEtNzcyMi00YmU0LTk2YTEtMThmMDA4NDI4NGEwLTEyNzMwNTY=/tiny/NAPC-Defense-Inc-.png

Source: NAPC Defense, Inc.

[ProfitScout]

$TKMO: Tekumo Announces 218% YoY Growth in Q3 2024 Results

New York, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Tekumo Inc. (TKMO or the "Company") announces its preliminary results for Q3, 2024.

Revenue for the first three quarters of 2024 increased 218% over the same period of 2023 to $2,884,632 vs. $1,320,616. Trailing twelve months revenues increased to $4, 283,956 from $1,680,298. Gross profit for the nine months increased 238% over the same period to $1,869,494 vs. $780,792 while continuing to maintain a 35% GPM. Operating expenses as a percentage of revenue decreased 16% during this period as well.

Tekumo Managed Services (TMS) continues to add significant breadth to our growing base of clients. Tekumo’s Chief Revenue Officer, Derrick Youngblood, stated “Our clients and prospects are looking to rapidly scale their technology driven businesses, not their bench of employees and contractors. They are interested in capturing actionable data on one platform that seamlessly integrates with their existing Field Service Management (FSM) systems. Our service platform, TekumoPRO, connects field service technicians, whether W2 or 1099, directly to our clients, in their existing environment, in real time. The flexibility to integrate and the depth of real time data is a game changer.”

“The TekumoPRO platform is really the future of work” says Tekumo CEO, Strings Kozisek. “We connect businesses with skilled and vetted local technicians and manage the entire service delivery process. Our robust analytics engine provides real-time data into financials, service metrics, and all measured KPIs in a way that does not exist in the industry today. Tekumo is extending our offering to include self-managed, assisted insourcing, and fully managed work orders, all backed with authentic data intelligence. We intend to fundamentally change how people are managed and how devices are installed, monitored and maintained.”

We encourage you to read our interim financial statements and notes for the quarter ended September 30, 2023, filed November 13 with OTC Markets.

CORPORATE OVERVIEW

The Company offers a field services delivery platform that solves the "last-mile" of installing, monitoring, and maintaining technology systems and smart connected devices. Distributed real-time data is at the core of all Tekumo offerings.

We play at the intersection of two major trends: the “Uber-ization” of product and service delivery, and the explosion of AI driven smart connected devices brought about by the “Industrial Internet of Things” (IIoT). Our Service Delivery platform is designed to intelligently automate the installation and maintenance of products by offering On-Demand local technician resources, as well as providing a “smart interface” for the monitoring and management of connected devices.

This service platform caters for a broad range of technologies from POS systems, kiosks, digital menu boards, print services, cameras, cabling, Wi-Fi and networking, as well as smart homes devices, wearable sensors, and access control.

Our platform results in “less people, less time and less cost” for our customers.

When we discuss our strategy, plans, future financial and operating performance, or other things that have not yet taken place, we are making statements considered to be forward-looking statements under United States (US) securities laws. Please see the disclosure relative to forward-looking statements at the base of this discussion.

About Tekumo, Inc.

Tekumo, Inc (OTC: TKMO) is an alternative reporting publicly held company that wholly-owns Tekumo LLC.

Safe Harbor:

Forward-Looking Statements

Any statements made in this press release which are not historical facts contain certain forward-looking statements, as such term is defined in the Private Security Litigation Reform Act of 1995, concerning potential developments affecting the business, prospects, financial condition and other aspects of the company to which this release pertains. The actual results of the specific items described in this release, and the Company's operations generally, may differ materially from what is projected in such forward-looking statements. Although such statements are based upon the best judgments of management of the Company as of the date of this release, significant deviations in magnitude, timing and other factors may result from business risks and uncertainties including, without limitation, the Company's dependence on third parties, general market and economic conditions, technical factors, the availability of outside capital, receipt of revenues and other factors, many of which are beyond the control of the company. The Company disclaims any obligation to update the information contained in any forward-looking statement. This press release shall not be deemed a general solicitation.

Colorado Springs
Phillip Dignan, President & CFO
719-419-6709
[e-mail]

https://www.globenewswire.com/newsroom/ti?nf=OTI3MzU1NiM2NTgyNjE5IzUwMDEwODg3MQ==
https://ml.globenewswire.com/media/NGM3OGM0M2UtNWY1MS00NTI4LWEzNmMtN2VkN2JhZTM3OGU1LTUwMDEwODg3MQ==/tiny/TEKUMO-Inc.png

Source: TEKUMO, Inc

[ProfitScout]

$BLIS (NAPC Defense) has issued 4 extremely positive announcements recently. These include a signed LOI on a $370 Million defense contract in the Middle East (See Oct. 22nd news below).

Oct. 29, 2024: NAPC Defense and Lamperd Less Lethal form Partnership for Security Products Marketing in The USA and Worldwide
https://www.morningstar.com/news/globe-newswire/9263212/napc-defense-and-lamperd-less-lethal-form-partnership-for-security-products-marketing-in-the-usa-and-worldwide

Oct. 25, 2024: NAPC Defense (OTCPK: BLIS) to Demonstrate Corner Shot and Attend SWAT Round-Up 2024 as a Convention Exhibitor

The Company Plans to Meet with leading SWAT Team Members, Law Enforcement Officers, Military Personnel, and other Industry Experts
https://www.globenewswire.com/en/news-release/2024/10/25/2969429/0/en/NAPC-Defense-OTCPK-BLIS-to-Demonstrate-Corner-Shot-and-Attend-SWAT-Round-Up-2024-as-a-Convention-Exhibitor.html

Oct. 24, 2024: NAPC Defense (OTCPK: BLIS) Awarded in Excess of $1 Million in Clean-up Contracts following Hurricanes Helene and Milton

The Company is Working on Additional Potential Restoration and Clean-up Contracts
https://finance.yahoo.com/news/napc-defense-otcpk-blis-awarded-120500313.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr

Oct. 22, 2024: NAPC Defense, Inc. (OTCPK: BLIS) issues Progress Report regarding Large Contract with Saudi Arabia
https://www.globenewswire.com/news-release/2024/10/22/2966948/0/en/NAPC-Defense-Inc-OTCPK-BLIS-issues-Progress-Report-regarding-Large-Contract-with-Saudi-Arabia.html

[ProfitScout]

$GNPX: Genprex Releases New Video Featuring Chief Medical Officer Discussing Positive Patient Outcomes in Two Lung Cancer Clinical Trials

Chief Medical Officer Provides Overview of Recent Positive Clinical Patient Outcomes

Video Highlights Recent Oncology Clinical Development Program Updates

AUSTIN, Texas, Aug. 15, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today released a new video featuring the Company's Chief Medical Officer, Mark Berger, MD, discussing positive clinical study updates from its Acclaim-1 and Acclaim-3 Phase 1/2 clinical trials in lung cancer and recent updates to the Company's oncology clinical development program.

The Acclaim-1 clinical trial is evaluating the combination of the Company's lead drug candidate, Reqorsa® Gene Therapy, and AstraZeneca's Tagrisso® to treat patients with late-stage NSCLC who have activating EGFR mutations and disease progression after treatment with Tagrisso.

The Acclaim-3 clinical trial is evaluating the combination of REQORSA and Genentech's Tecentriq® as a maintenance therapy to treat patients with extensive stage small cell lung cancer (ES-SCLC) who did not develop tumor progression after receiving Tecentriq and chemotherapy as initial standard treatment.

Dr. Berger remarked on the two positive patient outcomes in Acclaim-1:
"Both of these patients' outcomes are fairly remarkable in terms of their prolonged Progression Free Survival (PFS) among patients in the study who were progressing on their previous treatment when they came into the study. It's very compelling, particularly, that one of those patients has maintained this benefit for more than two years. And over time, the patients' side effects with the combination of REQORSA and Tagrisso have diminished rather than increased over time."

Dr. Berger's commentary on the positive patient outcome in Acclaim-3:
"In the Acclaim-3 study, the first patient treated in the Phase 1 dose escalation portion of the trial has had a positive response since enrollment and starting maintenance therapy. The patient has a partial remission (PR) from the start of maintenance therapy until after the second course, which is when the first CT scan is done. This is the first dose group in this study, and there is a second higher dose group to come. The patient's response is remarkable, and it is very unusual to have a PR during maintenance therapy. We believe these results bode very well for the study."

On recent updates to the Company's oncology clinical development program, Dr. Berger stated:
"To build on these positive patient results, we are making changes to our clinical development program both in the Acclaim-1 and Acclaim-2 studies. In the Acclaim-1 study, we are removing one of the cohorts in Phase 2a, which will allow us to advance more quickly. The Acclaim-2 study is being closed to further enrollment. It has been slow to enroll patients, mainly because there are hundreds of other very similar studies that evaluate new treatments after patients have progressed on Keytruda®. We certainly intend to continue to treat patients in this study until they have disease progression. We also believe closing to further enrollment is the right thing to do so that we can focus our limited resources on the fastest way to being able to enroll patients and get clinical data.

We're very excited by these positive patient responses, and we look forward to advancing REQORSA through the clinic. We believe that streamlining our efforts to do so is the best way to use our resources and to move our program forward."

To watch the video, please visit Genprex's website at https://www.genprex.com/videos/.

About Genprex, Inc.
Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex's technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. Genprex's oncology program utilizes its systemic, non-viral Oncoprex® Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The resultant product is administered intravenously, where it is taken up by tumor cells that then express tumor suppressor proteins that were deficient in the tumor. The Company's lead product candidate, Reqorsa® Gene Therapy (quaratusugene ozeplasmid), is being evaluated in two clinical trials as a treatment for NSCLC and SCLC. Each of Genprex's lung cancer clinical programs has received a Fast Track Designation from the FDA for the treatment of that patient population, and Genprex's SCLC program has received an FDA Orphan Drug Designation. Genprex's diabetes gene therapy approach is comprised of a novel infusion process that uses an AAV vector to deliver Pdx1 and MafA genes directly to the pancreas. In models of Type 1 diabetes, GPX-002 transforms alpha cells in the pancreas into functional beta-like cells, which can produce insulin but may be distinct enough from beta cells to evade the body's immune system. In a similar approach, GPX-002 for Type 2 diabetes, where autoimmunity is not at play, is believed to rejuvenate and replenish exhausted beta cells.

Interested investors and shareholders are encouraged to sign up for press releases and industry updates by visiting the Company Website, registering for Email Alerts and by following Genprex on Twitter, Facebook and LinkedIn.

Cautionary Language Concerning Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of management, are not guarantees of performance and are subject to significant risks and uncertainty. These forward-looking statements should, therefore, be considered in light of various important factors, including those set forth in Genprex's reports that it files from time to time with the Securities and Exchange Commission and which you should review, including those statements under "Item 1A – Risk Factors" in Genprex's Annual Report on Form 10-K for the year ended December 31, 2023.

Because forward-looking statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding: the initial patient responses to REQORSA treatments and the potential and promise of these responses, which are demonstrating early evidence of efficacy with a favorable safety profile; Genprex's ability to advance the clinical development, manufacturing and commercialization of its product candidates in accordance with projected timelines and specifications; the timing and success of Genprex's clinical trials and regulatory approvals; the effect of Genprex's product candidates, alone and in combination with other therapies, on cancer and diabetes; the effects of any strategic research and development prioritization initiatives, and any other efforts that Genprex takes or may take in the future that are aimed at optimizing and re-focusing Genprex's oncology and/or other clinical development programs including prioritization of resources, and the extent to which Genprex is able to implement such efforts and initiatives successfully to achieve the desired and intended results thereof; Genprex's future growth and financial status, including Genprex's ability to maintain compliance with the continued listing requirements of The Nasdaq Capital Market and to continue as a going concern and to obtain capital to meet its long-term liquidity needs on acceptable terms, or at all; Genprex's commercial and strategic partnerships, including those with its third party vendors, suppliers and manufacturers and their ability to successfully perform and scale up the manufacture of its product candidates; and Genprex's intellectual property and licenses.

These forward-looking statements should not be relied upon as predictions of future events and Genprex cannot assure you that the events or circumstances discussed or reflected in these statements will be achieved or will occur. If such forward-looking statements prove to be inaccurate, the inaccuracy may be material. You should not regard these statements as a representation or warranty by Genprex or any other person that Genprex will achieve its objectives and plans in any specified timeframe, or at all. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Genprex disclaims any obligation to publicly update or release any revisions to these forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this press release or to reflect the occurrence of unanticipated events, except as required by law.

Genprex, Inc.
(877) 774-GNPX (4679)

GNPX Investor Relations
[e-mail]

GNPX Media Contact
Kalyn Dabbs
[e-mail]

https://c212.net/c/img/favicon.png?sn=DA84592&sd=2024-08-15 View original content to download multimedia:https://www.prnewswire.com/news-releases/genprex-releases-new-video-featuring-chief-medical-officer-discussing-positive-patient-outcomes-in-two-lung-cancer-clinical-trials-302223226.html

SOURCE Genprex, Inc.

[ProfitScout]

$AVRW: Avenir Wellness Solutions Reports Fourth Quarter 2023 Results

New Initiatives Showing Encouraging Results

SHERMAN OAKS, CA / ACCESSWIRE / May 17, 2024 / Avenir Wellness Solutions, Inc. (OTCQB:AVRW) ("Avenir" or the "Company"), a proprietary broad platform technology and wellness company, today announced results for the fourth fiscal quarter ended December 30, 2023.

Key financial highlights for the fourth quarter included the following:

Net revenue in the fourth quarter of 2023 increased to $1.1 million from the same period in 2022 by $0.2 million, or 11.7%, and also increased sequentially from Q3 2023 by $43 thousand, or 4.4%. Overall growth was lower than expected due to the continued delay in receiving the expected remainder of the asset sale proceeds to be used for advertising and marketing to drive sales. The quarter did, however, benefit from a new relationship with leading online and beauty subscription box retailer, FabFitFun.

Gross margin increased 407 basis points year over year in the fourth quarter of 2023 due to improved working capital management offset in part by a higher proportion of sales coming from our wholesale channel of distribution with its lower margins than our higher-margin direct-to-consumer sales channel.

Gross margin for the third quarter of 2023 decreased sequentially from the second quarter of 2023 by 26 basis points due to a shift in sales channel mix with a higher proportion of wholesale sales to Amazon and FabFitFun which resulted in shipments of approximately $0.3 million.

Cost containment initiatives led to a favorable impact on SG&A expenses (excluding non-cash charges) for the fourth quarter with a decrease of $357 thousand in 2023 compared to 2022 driven by decreased spend on advertising and promotion of $325 thousand lower overhead by $32 thousand.

Net operating loss from continuing operations (excluding non-cash charges) improved by $0.9 million in 2023.

"Our products continue to maintain sales levels which is encouraging given that we have been unable to fully execute on our marketing initiatives pending receipt of the balance of the proceeds from the July 2022 asset sale. As mentioned in our third quarter earnings announcement, the proceeds from the July 2022 asset sale allow us to invest in the future of the Company, but the delay in receiving the balance of the proceeds continued to have an impact on our operating performance. We expect accelerating sales will reaffirm the improving overall trajectory of the business. Further, our margin expansion initiatives continue to deliver results with improvement from third quarter, and we continue our overall cost containment initiatives to further reduce SG&A expenses and to maximize operating leverage.

Fine tuning our Search Engine Optimization (SEO), bringing our media buying in house and achieving successful monthly campaigns like theSkimm continue to deliver for us as we execute on our strategy to build our brands," said Nancy Duitch, Avenir CEO.

Operational Highlights

Other operational highlights during the fourth quarter of 2023 included:

Our newly formulated Seratopical Revolution Cracked Heel Souffle was selected for inclusion in FatFitFun's Summer 2024 subscription box selling out an astonishing 80,000 units in under 43 minutes. Click link to view Instagram videos on our Cracked Heel Souffle.
Our DNA Complex hero product continues to perform as our subscription based grows.
Wholesale sales led by Amazon continue to grow with all the positive product reviews.
We began development of our new TikTok shop to capitalize on the evolving digital ecommerce landscape which launched in the second quarter of 2024.
For further details, please visit our website to review our most recent Form 10-K filed on May 17, 2024 at: http://www.avenirwellness.com/sec-filings/

About Avenir Wellness Solutions, Inc.

Avenir Wellness Solutions, Inc. (OTCQB:AVRW) is a broad platform technology company that develops proprietary wellness, nutraceutical, and topical delivery systems which are integrated into our wellness and beauty products and sold directly to the consumer. The technology, which is based on (15) fifteen current patents, offers a number of unique immediate- and controlled-release delivery vehicles designed to improve product efficacy, safety, and consumer experience for a wide range of active ingredients. The Company will continue down the path of creating new technologies that is part of its incubator strategy in order to monetize its intellectual property as well as expand our product lines utilizing the technology. As a vertically integrated platform company, Avenir looks to partner or license its IP technology with wellness companies worldwide. For more information visit: http://www.avenirwellness.com.

About The Sera Labs, Inc.

Sera Labs, a wholly owned subsidiary of Avenir, is a trusted leader in the health, wellness, and beauty sectors of innovative products with cutting-edge technology. Sera Labs creates high-quality products that use science-backed, proprietary formulations. More than 25 products are sold under the brand names Seratopical™, Seratopical Revolution™, SeraLabs™, and Nutri-Strips™. Sera Labs sells its products at affordable prices, making them easily accessible on a global scale. Strategically positioned in the growth market categories of beauty, health and wellness, Sera Labs products are sold direct-to-consumer (DTC) via online website orders, including a subscribe and save option, and also sold online and in-store at major national drug, grocery chains, convenience stores, and mass retailers and on Amazon.com. For more information visit: http://www.seralabshealth.com and follow Sera Labs on Facebook, Instagram and TikTok at @seratopical as well as on X (Twitter) at @sera_labs.

Forward Looking Statement

This press release contains "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, which statements are subject to considerable risks and uncertainties. Forward-looking statements include all statements other than statements of historical fact contained in this press release, including statements regarding the future growth and success of our organization. We have attempted to identify forward-looking statements by using words such as "anticipate," "believe," "could," "estimate," "expected," "intend," "may," "plan," "predict," "project," "should," "will," or "would," and similar expressions or the negative of these expressions.

Forward-looking statements represent our management's current expectations and predictions about trends affecting our business and industry and are based on information available as of the time such statements are made. Although we do not make forward-looking statements unless we believe we have a reasonable basis for doing so, we cannot guarantee their accuracy or completeness. Forward-looking statements involve numerous known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements predicted, assumed or implied by the forward-looking statements. Some of the risks and uncertainties that may cause our actual results to materially differ from those expressed or implied by these forward-looking statements are described in the section entitled "Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023, as well as in our Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission.

Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. Except as required by applicable law, we expressly disclaim any intent or obligation to update any forward-looking statements, or to update the reasons actual results could differ materially from those expressed or implied by these forward-looking statements, whether to conform such statements to actual results or changes in our expectations, or as a result of the availability of new information.

CONTACTS:

Investor Relations
Hanover International Inc.
T: [phone]
E: [e-mail]

[ProfitScout]

$IVDN News on sales surge for superior, energy saving house wrap: Innovative Designs Sales Update

PITTSBURGH, PA- (NewMediaWire) - May 30, 2024 - Innovative Designs, Inc. (OTCQB: IVDN) continues its upward sales trend into the end of May 2024. Year-to-date sales have already surpassed FYE2023 by over 33% with 5 months remaining in FYE2024. The growth is attributed to a substantial increase in the number of new retailers that are now carrying the company's Insultex House Wrap®. As new energy codes are implemented across the United States, homebuilders/contractors are using Insultex House Wrap® as a convenient R-Value continuous insulation to a wall system.

Our notable growth in sales can be attributed to Built Link Solutions (Formerly Compound Construction) based in Grand Rapids, MI. Built Link Solutions is working to become the primary source for industry professionals, innovators, and stakeholders to discover, evaluate, and adopt the latest advancements in building materials, tools and technologies. Having curated a comprehensive national distribution network, they bring pioneering solutions like Insultex House Wrap® to market, propelling the evolution of the construction industry towards a future where innovation thrives, and buildings meet the needs of tomorrow. Since coming onboard, Built Link Solutions has:

Established a comprehensive national distribution network to service customers where they are when they need it.

Grown national awareness of product benefits and specifications through their dedicated sales agents and attendance at building industry trade shows across the country.

Conducted in-person sales training and online seminars to educate sales associates on Insultex House Wrap®.

Streamlined the sales process to deliver consistent and superior level service to customers of all sizes and needs.

Implemented volume pricing models and incentive discounts to meet the needs for scale and demand.

As building codes and exterior R-Value requirements are quickly evolving across the country, Built Link Solutions has proven highly proactive in contacting prospective accounts, notifying them of the cost-effective solution that our Insultex House Wrap® provides.

Randy Kimbler, Director of Business Development for Built Link Solutions, commented, "Insultex House Wrap® is gaining traction in the market as it provides a timely and effective solution. Its cost-effectiveness, innovation, and ability to address today's building challenges are driving positive feedback nationwide."

About Innovative Designs, Inc.

Innovative Designs, Inc. manufactures the Insultex® House Wrap and Arctic Armor® Line, under the "i.d.i.gear" label featuring INSULTEX®. Patented INSULTEX® is the thinnest, lightest, and warmest insulator in the market today. For more information, please visit:
http://www.idigear.comorhttp://www.insultexhousewrap.com.

Disclaimer

Certain statements in this press release constitute "forward-looking" statements as defined by federal law. Such statements are based on assumptions, but there is no assurance that actual outcomes will not be materially different as those implied. Any such statements are made in reliance on the "Safe Harbor" protections provided under the Private Securities Reform Act of 1995 and are subject to various factors, including the risks and matters discussed in the Company's SEC filings available athttp://www.sec.gov.

CONTACT:

Innovative Designs, Inc.

Joseph Riccelli, CEO

412-799-0350
[e-mail]

http://www.insultexhousewrap.com

Built Link Solutions

Randy Kimbler, Dir. Business Development

616-443-3200

[e-mail]

News Source: Innovative Designs Inc

[ProfitScout]

$IVDN (16 million float) News on Rising Sales of Superior Insulation Product: Innovative Designs Vendor Growth

PITTSBURGH, PA, April 10, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- Innovative Designs, Inc. (OTCQB: IVDN) continues to gain market share through its growing vendor base. Since the beginning of this fiscal year (November 1, 2023), Innovative Designs has added over 30 new accounts that have purchased its Insultex House Wrap®. This has resulted in a comp sales increase of 318% as compared to the same time period last year (November 2022 – April 2023). With 7 months remaining in FY2024, sales for the first 5 months are approaching 88% of last year's total.

Randy Kimbler, a National Distributor of Insultex, commented, “The introduction of Insultex® House Wrap to several major building supply companies has been very well-received. The product is being placed in the retail locations of these organizations, as well as many local building supply companies. The R-6 insulation value provided by this very thin product has proven to be an affordable solution for builders facing economic challenges in states where energy codes require R-5 Continuous insulation for new construction.”

About Innovative Designs, Inc.

Innovative Designs, Inc. manufactures the Insultex® House Wrap and Arctic Armor® Line, under the "i.d.i.gear" label featuring INSULTEX®. Patented INSULTEX® is the thinnest, lightest and warmest insulator in the market today. For more information, please visit http://www.idigear.com or http://www.insultexhousewrap.com.

Disclaimer

Certain statements in this press release constitute "forward-looking" statements as defined by federal law. Such statements are based on assumptions, but there is no assurance that actual outcomes will not be materially different as those implied. Any such statements are made in reliance on the "Safe Harbor" protections provided under the Private Securities Reform Act of 1995 and are subject to various factors, including the risks and matters discussed in the Company's SEC filings available at http://www.sec.gov.

CONTACT:

Innovative Designs, Inc.

Joseph Riccelli, CEO
412-799-0350
[e-mail]
Website: http://www.insultexhousewrap.com

Link: https://finance.yahoo.com/news/innovative-designs-vendor-growth-173800119.html

[ProfitScout]

$AVRW: Avenir Wellness Solutions Issues 2024 Marketing Growth Plans to Shareholders for Seratopical Revolution Skin Care Line with Support from Nicole Kidman and Facial Plastic Surgeon Dr. Michael Persky

New TikTok Shop Ready for Launch to Help Grow Brand Awareness and Product Sales
News Link:
https://finance.yahoo.com/news/avenir-wellness-solutions-issues-2024-140000098.html

[ProfitScout]

$AVRW Feature: Media Grabbing Seratopical Revolution Skin Care Line, Personal Choice of Nicole Kidman for Years, Now Directly Recommended by LeadingLA Plastic Surgeon for Superior Anti-Aging Results
December 12, 2023
https://news.columbusnewsonline.com/story/478529/media-grabbing-seratopical-revolution-skin-care-line-personal-choice-of-nicole-kidman-for-years-now-directly-recommended-by-leadingla-plastic-surgeon-for-superior-antiaging-results-avrw.html?utm_source=dlvr.it&utm_medium=twitter

From the article:

– Proprietary Nutraceutical & Topical Delivery Systems for Wellness and Anti-Aging Beauty Product Lines.

– Company Currently Holds 15 Patents.

– Seratopical Revolution Skin Care Products are Promoted by the Company’s Global Brand Ambassador and Strategic Partner Nicole Kidman.

– LA-Based Facial Plastic Surgeon Dr. Michael Persky Directly Supporting Latest Seratopical DNA Complex Product.

– Media Exposure in Top-Tier Publications Including CNN Underscored, Page Six, PEOPLE Magazine, and More.

– Q3 Net Revenue Increased Sequentially from Q2 2023.

– Sales Expected to Increase Significantly During Q4 and Into 2024.

– Gross Margin Increased 80 Basis Points Quarter-to-Quarter with Further Expansion Expected in Q4.

– Upcoming Launch of New Beauty Product Releases &New Marketing Initiatives.

– Latest Sales Results Show Accelerating Strength via New Marketing Campaigns.

[ProfitScout]

$IVDN: Increasing Orders and Insider Share Purchase; Patented Evacuated Cell Insulation; Innovative Designs: Stock Symbol: IVDN
Click here:
https://www.einpresswire.com/article/637864225/increasing-orders-and-insider-share-purchase-patented-evacuated-cell-insulation-innovative-designs-stock-symbol-ivdn

From the article:

- $IVDN has a Very Small Stock Structure of Only 36 Million OS / 16 Million Float

- Sole Maker of Patented Insultex® Insulation Delivering Energy Saving Performance Far Superior to All Competition.

- Greater Energy Savings from Insultex® Insulation Delivers Essential Benefits of Economic Gains for the User and Carbon Reduction for the Environment.

- Significant New Orders for Insultex House Wrap® from Repeat Customers.

- Insider Buying from Board Member with Lockheed Martin & NASA Background.

- New US Patent Issued for Insultex® Manufacturing Process.

- International Distributor Agreement Signed with a Minimum Order Valued at $2 Million Per Year.

[Robertscott]

$KRTL ~ KRTL International Corp. had three team members participate as advisors alongside with Park Kyung-il, a professor of horticulture at Yeungnam University, and two professors in the evaluation of the hemp cultivation division of the Industrial Hemp Special Regulatory Free Zone in South Korea.

[Robertscott]

$KRTL ~ KRTL International Corp., a wholly owned subsidiary of KRTL Holding Group Inc. (OTC: KRTL), is an organization focused on green technology.

[Solarman]

$KRTL and $MMMW watch for innovations.

[Robertscott]

$KRTL ~ KRTL International Corp. had three team members participate as advisors alongside with Park Kyung-il, a professor of horticulture at Yeungnam University, and two professors in the evaluation of the hemp cultivation division of the Industrial Hemp Special Regulatory Free Zone in South Korea.

[Robertscott]

$KRTL ~ KRTL International Corp., a wholly owned subsidiary of KRTL Holding Group Inc. (OTC: KRTL), is an organization focused on green technology.

[Robertscott]

$KRTL ~ KRTL Biotech Inc., a wholly owned subsidiary of KRTL Holding Group, Inc. (OTC: KRTL), is a research and development company that has a focus in the biotechnology space.

[Robertscott]

$KRTL ~ KRTL Holding Group Inc. operates its wholly owned subsidiaries, KRTL Biotech, Inc. and KRTL International Corp.

[Robertscott]

$KRTL Medflow, an AI-powered telemedicine solution provider, combines best-in-class facial recognition biometrics with next-generation zero-trust security architecture to accurately verify patient identities. Their comprehensive suite of telemedicine tools, designed with security at the forefront, includes features like end-to-end encryption, facial recognition with ID scan, and HIPAA compliance. The platform allows healthcare providers to review and legally sign medical and legal documentation live with the patient, issue prescriptions, and capture patient vitals such as heart rate, blood pressure, breathing, and stress indicators, all using the patient's computer or mobile phone camera.

https://www.marketwatch.com/press-release/krtl-partnered-to-bring-comprehensive-cloud-and-endpoint-security-and-ai-powered-telemedicine-solutions-2023-05-30?mod=mw_quote_news_seemore

[Robertscott]

$PLPL The valuation, completed in Q1, 2023, highlights several key estimations that demonstrate the robustness of ByoPlanet's operations, ByoPlanet's enterprise value, and potential for long-term success.

https://seekingalpha.com/pr/19352540-third-party-valuation-firm-provides-estimated-valuation-of-byoplanets-subsidiary-of-plandai

[Da Stock Alpaca]

PPCB $.0003 with patents

[Let's Roll]

$EMED As the Company moves closer to production of the new next-generation flagship device, management plans to offer a special upgrade and exchange program to existing clients, which will be bundled with a lifetime warranty.

[Robertscott]

$EMED Our mission


Over 80 million Americans live with moderate to severe pain resulting from an accident or a disease, nearly 40% of them report being unable to find adequate pain relief and 77% report feeling depressed due to their chronic pain.
Our goal is to unlock the body’s natural ability to achieve wellness through high performance electrotherapy technologies, using energy, frequency and vibrations to improve quality of life.
Activists of a drug free approach, we take prescription drug misuse very seriously.
Alarming statistics have highlighted the importance of an alternative method for pain management.

https://electromedtech.com/our-mission/

[ProfitScout]

$ACGX management is moving forward on all the company's new ventures and is planning shareholder updates as soon as developments allow. From the company Twitter account:

$ACGX is making internal progress with multiple potential projects, discussions, and opportunities but nothing completed to discuss yet. We will update the public as soon as we can. #RealEstate #SecuredLending #CorporateAcquisitions #Investments #Consulting #PeopleVine #ACGX
Link:
https://twitter.com/ACGsocial/status/1635675708985946115

[Stockstax]

$TLIF ~ Share Cancellation Project Update: The case has now been filed with the Clerk's office to request the court grant an order to cancel over 34 million shares of $TLIF common stock. #ShareStructure #CleanUp

https://twitter.com/Tocca_Life/status/1630615972208951333

[ProfitScout]

$CDSG News: Company Enhances Management team and Clarifies Corporate Relationships

Las Vegas, NV., Feb. 15, 2023 (GLOBE NEWSWIRE) -- China Dongsheng International Inc., (OTC Markets: CDSG) (the "Company" or "CDSG") is pleased to announce it is strengthening our management team and is addressing shareholder inquiries regarding corporate business relationships.

The management of China Dongsheng International Inc, would like to report the company has no financial ties to either Chinese financial institutions or Chinese nationals. The company is a U.S based Delaware Corporation and has recently applied for a name change to Titan Lithium Inc which should assist in relieving confusion regarding the proprietorship and direction of business.

Michael Noonan, JD, MBA has been appointed Vice President of Finance. Michael's strengths include corporate governance, corporate finance, initial public offerings, strategic planning and analysis. He has worked in many jurisdictions including the United States, Canada, European Union, as well as several countries in the Middle East and Asia. Michael also serves on several public company boards. Michael holds a BBA in Business Administration and Economics, a Masters of Business Administration and an Executive JD from Concord Law School at Purdue University Global.

Norm Shunda has been appointed as Head of Logistics and Infrastructure development. Mr. Shunda is presently owner of Weekes Construction Group having grown the business continually over the last ten years. Norm is highly skilled in negotiations, sales and providing exceptional service transactions.

About the Company: China Dongsheng International Inc. (OTC Markets: CDSG), through its wholly owned subsidiary Titan Lithium, is a lithium explorer and developer.

Contact:

Harp Sangha-Chairman

[e-mail]

1-702-595-2247

http://www.titanlithiuminc.com

Company Disclaimers: As a "penny stock" Company, within the meaning of federal and state securities law, China Dongsheng International Inc. may not avail itself of the Safe Harbor provisions as identified in the Private Securities Litigation Reform Act of 1995. However, CDSG provides the following disclaimer and warning to protect our shareholders, prospective investors and the public at large by alerting them to the risks and uncertainties involved with any investment, and the need to perform their own due diligence and assessment.

Forward-Looking Statements:

This press release may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to financial results and plans for future development activities and are thus prospective. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief or current expectations of the Company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company's ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the factors that could cause actual results to differ materially from those indicated in the forward-looking statements are risks and uncertainties associated with the Company's business and finances in general, including the ability to continue and manage its growth, competition, global economic conditions and other factors discussed in detail in the Company's periodic filings with the Security and Exchange Commission.